Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/9472
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Klinkenberg-Knol, E. | - |
dc.contributor.author | Nelis, F. | - |
dc.contributor.author | Dent, J. | - |
dc.contributor.author | Snel, P. | - |
dc.contributor.author | Mitchell, B. | - |
dc.contributor.author | Prichard, P. | - |
dc.contributor.author | Lloyd, D. | - |
dc.contributor.author | Havu, N. | - |
dc.contributor.author | Frame, M. | - |
dc.contributor.author | Roman, J. | - |
dc.contributor.author | Walan, A. | - |
dc.date.issued | 2000 | - |
dc.identifier.citation | Gastroenterology, 2000; 118(4):661-669 | - |
dc.identifier.issn | 0016-5085 | - |
dc.identifier.issn | 1528-0012 | - |
dc.identifier.uri | http://hdl.handle.net/2440/9472 | - |
dc.description.abstract | <h4>Background & aims</h4>The efficacy and safety of long-term acid suppression remains a subject for debate. We report data from patients with refractory reflux esophagitis who were undergoing maintenance therapy with >/=20 mg omeprazole daily for a mean period of 6.5 years (range, 1.4-11.2 years).<h4>Methods</h4>Patients with severe reflux esophagitis resistant to long-term therapy with H(2)-receptor antagonists and who were not eligible for surgery were evaluated at least annually for endoscopic relapse and histological changes in the gastric corpus.<h4>Results</h4>In 230 patients (mean age, 63 years at entry; 36% were >/=70 years), there were 158 relapses of esophagitis during 1490 treatment years (1 per 9.4 years), with no significant difference in relapse rates between Helicobacter pylori-positive and -negative patients. All patients rehealed during continued therapy with omeprazole at the same or higher dose. The annual incidence of gastric corpus mucosal atrophy was 4.7% and 0.7% in H. pylori-positive and -negative patients, respectively, which was mainly observed in elderly patients who had moderate/severe gastritis at entry. In patients with baseline moderate/severe gastritis, the incidences were similar: 7.9% and 8.4%, respectively. Corpus intestinal metaplasia was rare, and no dysplasia or neoplasms were observed. The adverse event profile was as might be expected from this elderly group of patients.<h4>Conclusions</h4>Long-term omeprazole therapy (up to 11 years) is highly effective and safe for control of reflux esophagitis. | - |
dc.language.iso | en | - |
dc.publisher | W B Saunders Co | - |
dc.source.uri | http://dx.doi.org/10.1016/s0016-5085(00)70135-1 | - |
dc.subject | Long-Term Study Group | - |
dc.subject | Gastric Mucosa | - |
dc.subject | Humans | - |
dc.subject | Helicobacter Infections | - |
dc.subject | Barrett Esophagus | - |
dc.subject | Gastroesophageal Reflux | - |
dc.subject | Esophagitis | - |
dc.subject | Gastritis | - |
dc.subject | Hyperplasia | - |
dc.subject | Omeprazole | - |
dc.subject | Gastrins | - |
dc.subject | Anti-Ulcer Agents | - |
dc.subject | Treatment Outcome | - |
dc.subject | Drug Resistance | - |
dc.subject | Time Factors | - |
dc.subject | Adolescent | - |
dc.subject | Adult | - |
dc.subject | Aged | - |
dc.subject | Aged, 80 and over | - |
dc.subject | Middle Aged | - |
dc.subject | Child | - |
dc.subject | Female | - |
dc.subject | Male | - |
dc.title | Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1016/S0016-5085(00)70135-1 | - |
pubs.publication-status | Published | - |
Appears in Collections: | Aurora harvest Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.